Research Article
Effect of Denosumab on Glucose Homeostasis in Postmenopausal Women with Breast Cancer Treated with Aromatase Inhibitors: A Pilot Study
Table 1
Clinical and biochemical features of the postmenopausal breast cancer patients at baseline and 5 months after 60 mg Dmab injection.
| | | Baseline | 5 months | value |
| | Weight (kg) | 58.7 ± 13.0 | 57.8 ± 13.0 | 0.30 | | BMI (kg/m2) | 23.5 ± 4.6 | 23.3 ± 5.0 | 0.39 | | Waist circumference (cm) | 81.7 ± 12.2 | 77.4 ± 16.4 | 0.12 | | Serum alb-corr calcium (mg/dL) | 9.7 ± 0.4 | 9.6 ± 0.4 | 0.81 | | Serum phosphate (mg/dL) | 3.5 ± 0.4 | 3.3 ± 0.4 | 0.56 | | Serum 25OHD (ng/mL) | 34.3 ± 11.3 | 33.8 ± 11.6 | 0.90 | | Plasma PTH (pg/mL) | 36.1 ± 14.1 | 49.6 ± 14.6 | 0.008 | | Total ALP (U/L) | 88.9 ± 25.2 | 58.7 ± 6.9 | 0.045 | | Serum CTX (ng/mL) | 0.7 ± 0.3 | 0.1 ± 0.1 | 0.002 | | HbA1c (mmol/mol) | 36.0 ± 2.3 | 39.6 ± 3.1 | 0.01 |
|
|
BMI, body mass index; alb-corr, albumin-corrected; 25OHD, 25-hydroxyvitamin D; PTH, parathormone; ALP, alkaline phosphatase; CTX, C-terminal telopeptide of type 1 collagen; HbA1c, glycated haemoglobin.
|
